Literature DB >> 21516485

Eleven years of experience with AIDS-related lymphomas at the Institute of Oncology Ljubljana.

Tanja Mesti1, Tanja Južnič Setina, Marjeta Vovk, Barbara Jezeršek Novaković.   

Abstract

Neoplastic diseases are currently recognized in more than 40% of HIV sero-positive patients, with AIDS-related lymphomas (ARL) being most common. A survey of the ARLs in patients attending our institute from 1998 to 2009 is given along with the clinical and pathological manifestations, treatment and outcomes. We conducted a retrospective chart review of patients treated for ARL between 1998 and 2009 at the Institute of Oncology Ljubljana. Patients were identified from the lymphoma database of our institute. Eight patients with ARL were diagnosed and treated at our Institute according to the then protocol for HIV sero-negative lymphoma patients. Seven patients received HAART. Six patients received prophylaxis for opportunistic infections and febrile neutropenia (FN), and 6 of them had at least one episode of FN. Seven patients are still alive and in complete remission 7-142 months after the diagnosis of ARL. One of the patients died of progressive lymphoma. The low incidence of ARL in the HIV-infected population, early stages at the presentation and the good response to treatment are not in accordance with the data from the literature. Whether this goes on account of the HAART treatment, prophylaxis for opportunistic infections and FN or a better follow-up of these patients remains to be answered. Also, the group is very small to make any definitive conclusions.

Entities:  

Mesh:

Year:  2011        PMID: 21516485     DOI: 10.1007/s12032-011-9951-7

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  33 in total

1.  Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.

Authors:  L D Kaplan; D J Straus; M A Testa; J Von Roenn; B J Dezube; T P Cooley; B Herndier; D W Northfelt; J Huang; A Tulpule; A M Levine
Journal:  N Engl J Med       Date:  1997-06-05       Impact factor: 91.245

Review 2.  Molecular biology of Burkitt's lymphoma.

Authors:  J L Hecht; J C Aster
Journal:  J Clin Oncol       Date:  2000-11-01       Impact factor: 44.544

Review 3.  Recent advances in acquired immunodeficiency syndrome (AIDS)-related lymphoma.

Authors:  Soon Thye Lim; Alexandra M Levine
Journal:  CA Cancer J Clin       Date:  2005 Jul-Aug       Impact factor: 508.702

4.  Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology.

Authors:  Richard F Little; Stefania Pittaluga; Nicole Grant; Seth M Steinberg; Mark F Kavlick; Hiroaki Mitsuya; Genoveffa Franchini; Martin Gutierrez; Mark Raffeld; Elaine S Jaffe; Gene Shearer; Robert Yarchoan; Wyndham H Wilson
Journal:  Blood       Date:  2003-02-27       Impact factor: 22.113

Review 5.  Lymphomas in the immunocompromised patient.

Authors:  M D DeMario; D N Liebowitz
Journal:  Semin Oncol       Date:  1998-08       Impact factor: 4.929

6.  Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals.

Authors:  Alina Burgi; Stephanie Brodine; Scott Wegner; Mark Milazzo; Mark R Wallace; Katherine Spooner; David L Blazes; Brian K Agan; Adam Armstrong; Susan Fraser; Nancy F Crum
Journal:  Cancer       Date:  2005-10-01       Impact factor: 6.860

7.  Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Trial (E1494).

Authors:  Joseph A Sparano; Sandra Lee; Michael G Chen; Tipu Nazeer; Avi Einzig; Richard F Ambinder; David H Henry; Jane Manalo; Tianhong Li; Jamie H Von Roenn
Journal:  J Clin Oncol       Date:  2004-04-15       Impact factor: 44.544

8.  Human immunodeficiency virus-related lymphoma. Prognostic factors predictive of survival.

Authors:  A M Levine; J Sullivan-Halley; M C Pike; M U Rarick; C Loureiro; M Bernstein-Singer; E Willson; R Brynes; J Parker; S Rasheed
Journal:  Cancer       Date:  1991-12-01       Impact factor: 6.860

Review 9.  Emerging pathways in the development of AIDS-related lymphomas.

Authors:  Antonino Carbone
Journal:  Lancet Oncol       Date:  2003-01       Impact factor: 41.316

Review 10.  AIDS-associated malignancies.

Authors:  A S Akanmu
Journal:  Afr J Med Med Sci       Date:  2006-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.